Overexpression of ENO1 has been shown to enhance tamoxifen resistance in breast cancer, and promote cisplatin resistance in gastric cancer cells by stimulating glycolysis, as well as methotrexate resistance in human HT29 cells (37). Here, ENO1 is linked to breast carcinoma.